#3 - Pfizer (NYSE:PFE)
If anyone stands to benefit from the recently-passed tax reform bill, It's Pfizer (NYSE: PFE). The company has struggled to stay competitive due to its high tax rate and massive overseas cash pile. The company even attempted to buy AstraZeneca (AZN) and Allergan (AGN) in order to be able to move its headquarters to Europe and lower its corporate tax rate. Regulators shut down both deals before Pfizer could execute on them.
Pfizer has $160 billion in profit sitting overseas. Before the tax bill, it would have had to pay 35% tax if it wanted to bring that money back to the United States. Now, it can pay just 14% on those taxes thanks to the Tax Reform Act. As Pfizer sees a major influx of capital, it's likely to increase M&A activity, pay a higher dividend and buyback shares of its own stock.
The company has already boosted its dividend by 6% to 34 cents per share and has announced that it will be buying back $10 billion of its own shares since the tax reform bill passed. This is on top of a previously-announced $6.4 billion buyback plan.
Pfizer could easily be one of the best Dow Jones stocks to hold in the new year as these spending programs begin to take shape.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More - Current Price
- $25.06
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.92 (31.4% Upside)
